racotumomab

Racotumomab (originally known as 1E10 mAb) is an anti-idiotype murine IgG1 directed to membrane glycoconjugates expressed in aggressive solid tumors and an anti-idiotype murine monoclonal antibody (MoAb) specific to P3 MoAb with anti-metastatic effect. It was developed as a mirror image of the idiotype of another antibody against N-glycolyl-containing molecules, such as the NeuGcGM3 ganglioside. Its trade name is Vaxira, which is developed for non-small cell lung cancer (NSCLC) vaccine by researchers at the Center of Molecular Immunology, Cuba in collaboration with researchers from the Buenos Aires University, Argentina. It was granted certificate of approval by the State Center for Quality Control of Medicines of Cuba and by January 2013 was used as the primary treatment for NSCLC independent of the disease stage. It induces the patient's immune system to generate a response against a cancer-specific molecular target with the purpose of blocking tumor growth, slowing disease progression and ultimately increasing patient survival. Unlike traditional treatments for cancer with chemotherapy and radiation whereby healthy cells are attacked alongside cancerous ones, racotumomab is a well-tolerates cancer treatment with the most common side effect is burning in the arm and slight pain in the injection area as well as a possibility of asthenia.